Additionally in the ATAC trial, the difference in breast cancer recurrence in patients reporting vasomotor symptoms compared to women without vasomotor symptoms was small and of borderline significance overall [ 26 ].
← all excerpts
Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial.
1
—
—